XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. is a clinical-stage biotech company dedicated to the development of innovative pharmaceutical products aimed at treating autoimmune diseases, with a particular focus on lupus. XTL Biopharmaceuticals is committed to advancing healthcare through cutting-edge research and development. The company’s primary address is located at 5 HaCharoshet St., Raanana, 4365603, IL.

The lead drug candidate, hCDR1, represents a significant clinical asset in the treatment of systemic lupus erythematosus (SLE). Recognizing the limitations and side effects associated with current SLE treatments, XTL Biopharmaceuticals has dedicated substantial resources to developing more effective and safer alternatives. The extensive clinical data supporting hCDR1 includes three clinical trials involving 400 patients, along with over 200 preclinical studies. These findings have been published in more than 40 peer-reviewed scientific journals, underscoring the rigor and validity of XTL Biopharmaceuticals' research.

XTL Biopharmaceuticals Ltd. continues to push the boundaries of pharmaceutical innovation, striving to improve the lives of patients affected by autoimmune conditions. We invite the manager of XTL Biopharmaceuticals to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work and connect with a broader audience.